Skip to content
- ESLA: Two Infusions, One Patient—and a Bigger Cancer-Therapy Question
- AMOD: Bitcoin Riches Meet the Per-Share Value Test
- AHT: A $17 Million Fee Waiver Changes Ashford’s Liquidity Story
- INVE: A $20 Million Tender Offer Puts a Price on Shareholder Returns
- OLOX: From Natural Gas to Computing Power—The Execution Test Begins
- HOST: A Buyback Headline Lifts the AI Data-Center Story—Now Comes the Funding Test
- PRSO: A $2 Million Wireless Order Gives Peraso’s Rally a Concrete Catalyst
- ANNX: Can Annexon Protect Vision? A Major Clinical Test Approaches
- ADAG: A Masked Cancer Treatment Moves Toward Its First Human Test
- RBBN: The Technology Behind New York’s Transit Communications Gets an Upgrade
